Botox and Xeomin are both FDA-cleared botulinum toxin Type A (BoNT-A) neuromodulators, but they are not interchangeable. The critical difference lies in their formulation: Botox is complexed with accessory proteins (100 units per 1 mL vial), while Xeomin is a naked toxin—stripped of those proteins during manufacturing. That distinction drives differences in onset speed, dosing requirements, patient response, and your acquisition cost.
Injectables
Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients
Both are FDA-approved botulinum toxin Type A products, but their formulations, onset profiles, dosing economics, and patient candidacy differ in ways that matter to your bottom line and clinical outcomes.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |